Cavitation, low density areas, and stenosis of responsible bronchus are risk factors for infectious complications after endobronchial ultrasound-guided transbronchial biopsy.
An individualized model for predicting lung function trajectory and risk for airflow limitation was recently validated for the general population.
Pulmonary rehabilitation programs represent a key component in the management of patients with chronic obstructive pulmonary disease.
Gefapixant 50 mg twice daily significantly reduced cough frequency in patients with refractory chronic cough and unexplained chronic cough after 12 weeks.
Merck announced topline data from 2 ongoing pivotal phase 3 trials (COUGH-1 and COUGH-2) for gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough.
Exposure to low ambient air ozone levels may produce adverse health effects in children with asthma.
In older women, the risk for major osteoporotic fracture is not associated with long-term inhaled corticosteroid use and consequent respiratory diseases.
We spoke with the founding director of the Center for Pulmonary Infection Research and Treatment, Charles Dela Cruz, MD, PhD, of Yale University to get a better understanding of the risks that COVID-19 may pose to patients with chronic lung disease.
Better adherence to medication is associated with improved health-related quality of life in sarcoidosis.
An increase in PM2.5 was associated with an increased risk for all-cause out-of-hospital cardiac arrest on the same day.
A total of 7 differentially methylated CpG sites associated with mortality in people with ≥10 pack-years smoking history were identified in a genome-wide analysis.
During the period from 2010 to 2016, parents of children from low-income households were more likely to report recent childhood GI and respiratory illnesses than parents with a higher income.
Using inhaled corticosteroids in higher doses for longer durations was associated with tracheobronchomalacia.
The FDA has granted 510(k) clearance to the Hyperfine system, a bedside magnetic resonance imaging system.
Organizations including the CDC and FDA have been investigating the nationwide outbreak of e-cigarette or vaping product use–associated lung injury since August 2019.